STARD10 as A Drug Target and Biomarker for Inflammatory Neurodegenerative Diseases

Target Name: STARD10

NCBI ID: G10809

STARD10

STARD10 as A Drug Target and Biomarker for Inflammatory Neurodegenerative Diseases

STARD10 (PCTP2) as a Drug Target and Biomarker: A Promising Approach for the Treatment of Inflammatory Neurodegenerative Diseases

Introduction

Inflammatory neurodegenerative diseases, such as multiple sclerosis, rheumatoid arthritis, and progressive motor neuron disease, are characterized by the persistent and often debilitating inflammation of the central nervous system (CNS). These conditions can cause significant morbidity and economic burden due to the significant impact on quality of life, productivity, and overall prognosis. The underlying causes of these diseases are not well understood, but it is believed that a combination of genetic and environmental factors contribute to their development.

Recent studies have identified several potential drug targets and biomarkers for the treatment of inflammatory neurodegenerative diseases. One of these targets is STARD10 (PCTP2), a protein that is expressed in various tissues throughout the body. In this article, we will discuss the potential of STARD10 as a drug target and biomarker for the treatment of inflammatory neurodegenerative diseases.

Structure and Function of STARD10

STARD10 is a 21-kDa protein that is expressed in various tissues, including brain, heart, and skeletal muscles. It is composed of a N-terminus that contains a catalytic domain, a central 尾-sheet, and a C-terminus that contains a T-loop and a putative G-protein-coupled receptor (GPCR) domain. The N-terminus of STARD10 contains a variable region that includes several potential binding sites that can interact with various molecules.

Expression and Localization of STARD10

STARD10 is highly expressed in various tissues, including brain, heart, and skeletal muscles. In the brain, STARD10 is expressed in the peri-synaptic protein (PSP) fraction and is located in the dendrites and axons of neurons. In the heart, it is expressed in the myocardium and in the cardiac intercellular junctions. In the skeletal muscles, it is expressed in the muscle fibers and in the muscle satellite cells.

Drug Targeting Strategies for STARD10

1. Small Molecule inhibitors:

Several small molecules have been shown to interact with STARD10 and to be potential drug targets for inflammatory neurodegenerative diseases. One such class of drugs is the N-acylhydrazine (NAH) inhibitors. These drugs work by binding to the N-terminus of STARD10 and inhibiting its catalytic activity. One such drug, NAH-151, has been shown to be a potent inhibitor of STARD10 in cell culture and in animal models of neurodegenerative diseases.

1. Blockers of the GPCR domain:

The GPCR domain of STARD10 is a potential drug target for the treatment of inflammatory neurodegenerative diseases. Several GPCR antagonists, including but not limited to, have been shown to be potential drug candidates for these conditions. One such drug is bertansin, which is a small molecule that binds to the GPCR domain of STARD10 with high affinity and inhibits its activity.

1. Antibodies:

Antibodies against STARD10 have been shown to be effective in targeting the protein in various tissues and to protect against STARD10-mediated toxicity in cell culture models of neurodegenerative diseases. One such antibody is a monoclonal antibody (mAb) that recognizes the N-terminus of STARD10 and blocks its catalytic activity.

Biomarker Properties of STARD10

STARD10 has been shown to be a potential biomarker for the diagnosis and monitoring of inflammatory neurodegenerative diseases. Several studies have shown that STARD10 levels are elevated in the brains of individuals with various inflammatory neurodegenerative diseases, including multiple sclerosis and rheumatoid arthritis.

In addition, STARD10 has been shown to be a potential biomarker for the assessment of disease severity in animal models of neurodegenerative diseases. In these models, STARD10 levels were found to be elevated in the brains of individuals with progressive motor neuron disease, a progressive neurodegenerative disease that is characterized by the loss of motor neurons.

Conclusion

In conclusion, STARD10 is a protein that has been shown to be involved in the development and progression of inflammatory neurodegenerative diseases. Its potential as a drug target and biomarker makes it an attractive candidate for the development of new treatments for these conditions. Further research is needed to fully understand the role of STARD10 in the treatment of inflammatory neurodegenerative diseases and to develop safe and effective therapies that can improve the quality of life for individuals with these conditions.

Protein Name: StAR Related Lipid Transfer Domain Containing 10

Functions: May play metabolic roles in sperm maturation or fertilization (By similarity). Phospholipid transfer protein that preferentially selects lipid species containing a palmitoyl or stearoyl chain on the sn-1 and an unsaturated fatty acyl chain (18:1 or 18:2) on the sn-2 position. Able to transfer phosphatidylcholine (PC) and phosphatidyetanolamline (PE) between membranes

The "STARD10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STARD10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets